[HTML][HTML] 晚期非小细胞肺癌靶向治疗进展与展望： 聚焦小分子酪氨酸激酶抑制剂
张国伟 - Chinese Journal of Lung Cancer, 2017 - ncbi.nlm.nih.gov
… The epidermal growth factor tyrosine kinase inhibitors such as gefitinib, erlotinib, icotinib
and anaplastic lymphoma kinase tyrosine kinase inhibitors crizotinib have brought a milestone …
and anaplastic lymphoma kinase tyrosine kinase inhibitors crizotinib have brought a milestone …
综述. 肺癌细胞中HGF/c-Met 信号通路的异常调控及其靶向药物研究进展.
李永文， 刘红雨， 陈军 - Chinese Journal of Lung Cancer, 2014 - search.ebscohost.com
… Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in
previously treated non-small-cell lung cancer. J Clin Oncol, 2011, 29(24): 3307-3315. …
previously treated non-small-cell lung cancer. J Clin Oncol, 2011, 29(24): 3307-3315. …
[HTML][HTML] 老年晚期非小细胞肺癌患者药物治疗现状和趋势
周剑平， 高蓓莉 - Chinese Journal of Lung Cancer, 2011 - ncbi.nlm.nih.gov
… Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in
patients age 70 to 89: IFCT-0501 randomized phase Ⅲ study in advanced non-small cell lung …
patients age 70 to 89: IFCT-0501 randomized phase Ⅲ study in advanced non-small cell lung …
腔面型乳腺癌内分泌治疗耐药的机制与治疗进展
H ZHANG, X ZHU, X JIN… - 中国临床药理学与治疗 …, 2023 - manu41.magtech.com.cn
… analysis of the BOLERO-2 clinical trial[J]. JAMA Oncol, 2016, … Phase II, randomized trial to
compare anastrozole combined … Effect of pembrolizumab plus neoadjuvant chemotherapy on …
compare anastrozole combined … Effect of pembrolizumab plus neoadjuvant chemotherapy on …
[HTML][HTML] EGFR 抑制剂在胃癌中的研究进展
涂金花， 余英豪 - 世界华人消化杂志, 2011 - wjgnet.com
胃癌是常见的消化系恶性肿瘤, 传统的化疗和放疗效果均不甚理想. 表皮生长因子受体(epidermal
growth factor receptor, EGFR) 信号转导通路在胃癌细胞的增殖, 血管生成, 侵袭, 转移等方面有…
growth factor receptor, EGFR) 信号转导通路在胃癌细胞的增殖, 血管生成, 侵袭, 转移等方面有…
[HTML][HTML] IB 期肺腺癌患者辅助治疗方案的筛选
申磊磊， 陈莹， 云天洋， 郭俊唐， 柳曦… - Journal of Southern …, 2024 - ncbi.nlm.nih.gov
… and hematological suppression and gastrointestinal reactions for chemotherapy, and TKIs
were associated with a … Adjuvant chemotherapy does not improve DFS or OS in patients with …
were associated with a … Adjuvant chemotherapy does not improve DFS or OS in patients with …
转移性结直肠癌抗血管生成靶向治疗的研究进展.
夏秀娟， 李粉婷， 刘佳， 高欣欣… - Progress in Modern …, 2016 - search.ebscohost.com
… Randomized phase II trial of cetuximab, … -2 study[J]. J Clin Oncol, 2007, 25(29): 4557-4561
[34] Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, …
[34] Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, …
[HTML][HTML] 双途径化疗联合伽玛刀治疗局部晚期胰腺癌12 例
夏念信， 邱宝安， 温居一， 祝建勇， 刘澎 - 世界华人消化杂志, 2009 - wjgnet.com
… venous chemotherapy… two-pathway chemotherapy. The curative effect, relief extent of pain,
life span and the adverse reaction were compared in the course of treatment between the two …
life span and the adverse reaction were compared in the course of treatment between the two …
晚期结肠癌个体化治疗策略探讨
杨冬阳， 马冬 - 循证医学, 2014 - jebm.cn
… , a large randomized phase Ⅱ study of maintenance therapy or chemotherapy-free intervals
… Bevacizumab (Bev) with or without Erlotinib as maintenance therapy, following induction first…
… Bevacizumab (Bev) with or without Erlotinib as maintenance therapy, following induction first…
[HTML][HTML] 肺癌治疗的现状与进展
杨志， 林春龙 - Advances in Clinical Medicine, 2018 - hanspub.org
… , chemotherapy and radiotherapy are the main treatments for lung cancer. However, only
20% to 30% patients are clinically suitable for surgical treatment. The traditional chemotherapy …
20% to 30% patients are clinically suitable for surgical treatment. The traditional chemotherapy …